

**Fiscal Year 2026 Congressionally Directed Medical Research Programs
Ovarian Cancer Research Program (OCRP)
Reference Table of Award Mechanisms and Submission Requirements**

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Trial Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942526OCRPTA</p>	<p>Independent investigators at all academic levels.</p>	<ul style="list-style-type: none"> • Supports rapid implementation of clinical trials with the potential to significantly impact ovarian cancer. • Proposed projects may range from small, proof-of concept trials through large-scale, definitive trials, including early-phase or pilot clinical trials (phase 0, 1 or 1/2). • Applications require preliminary data. Larger, more definitive clinical trials, including expansion of previous promising pilot trials, must include preliminary data with respect to safety in an ovarian cancer population. • Submission of a Letter of Intent is required prior to full application submission. 	<ul style="list-style-type: none"> • The maximum period of performance is 4 years. • The maximum allowable funding for the entire period of performance is \$2.8 million (M) for total costs. * 	<p>Pre-Application (Letter of Intent): September 15, 2026 5:00 p.m. Eastern time</p> <p>Application: October 1, 2026 11:59 p.m. Eastern time</p>
<p>Investigator-Initiated Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942526OCRPIIRA</p>	<p>Investigators at or above the level of Assistant Professor, or equivalent.</p> <p>Partnering Principal Investigator (PI) Option: Up to two investigators may collaborate on a single application, each of whom will serve as a PI and receive a separate award.</p>	<ul style="list-style-type: none"> • Supports high-impact research that addresses a critical need and demonstrates the potential to make an important contribution to ovarian cancer or patient/survivor care. <ul style="list-style-type: none"> ○ Applications cannot support clinical trials. ○ Applications proposing research on cell lines or animals must provide justification for use. ○ Research aimed at extending the lives of advanced state and recurrent patients encouraged. ○ Applications require preliminary data. • Submission of a Preproposal is required; full application submission is by invitation only. 	<ul style="list-style-type: none"> • The maximum period of performance is 4 years. • Single PI: maximum allowable funding for the entire period of performance is \$1.05M for total costs. * • Partnering PI Option: Maximum allowable funding for the entire period of performance is \$1.40M for total costs. * 	<p>Pre-Application (Preproposal): July 13, 2026 5:00 p.m. Eastern time</p> <p>Application: October 1, 2026 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Ovarian Cancer Academy – Early-Career Investigator Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942526OCRPOCAECI</p>	<p>Investigators must be within five years of their last postdoctoral research position or clinical fellowship or equivalent as of the full application submission deadline.</p> <p>Requires a letter attesting to eligibility.</p>	<ul style="list-style-type: none"> • Supports the addition of new early-career investigators to the unique, interactive, virtual academy that provides intensive mentoring, national networking, collaborations and a peer group for junior faculty. <ul style="list-style-type: none"> ○ Encourages applications from ECIs limited by lack of resources or other overwhelming obstacles, impacting their ability to commit to conducting ovarian cancer research. ○ Requires a designated mentor who is an experienced ovarian cancer researcher with ovarian cancer funding. ○ The ECI and designated mentor may originate from different institutions. ○ Applications cannot support clinical trials. An ECI that wishes to propose a clinical trial may refer to the Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award mechanism. ○ Investigators who apply to both the Ovarian Cancer Academy – Early-Career Investigator Award and the Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award mechanisms may not accept an award from both mechanisms. 	<ul style="list-style-type: none"> • The maximum period of performance is 4 years. • The maximum allowable funding for the entire period of performance is \$1.125M for total costs.* 	<p>Pre-Application (Letter of Intent): September 15, 2026 5:00 p.m. Eastern time</p> <p>Application: October 1, 2026 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Ovarian Cancer Clinical Trial Academy – Early Career Investigator Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942526OCRPOCCTAECI</p>	<p>Investigators must be within 12 years of their last postdoctoral research position or clinical fellowship or equivalent as of the full application submission deadline.</p> <p>Requires a letter attesting to eligibility.</p>	<ul style="list-style-type: none"> • Supports the addition of new ECIs to the unique, interactive, virtual Clinical Trial Academy that provides intensive mentoring, national networking, collaborations and a peer group for junior faculty. <ul style="list-style-type: none"> ○ Encourages applications from ECIs limited by lack of resources or other overwhelming obstacles, impacting their ability to commit to conducting ovarian cancer research. ○ Requires a designated mentor with clinical trial experience and an active clinical trial. ○ A designated mentor may only mentor one ECI. ○ The ECI and designated mentor may originate from different institutions. ○ Applications require preliminary data. ○ Clinical trials allowed. ○ Investigators who apply to both the Ovarian Cancer Academy – Early-Career Investigator Award and the Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award mechanisms may not accept an award from both mechanisms. • Submission of a Letter of Intent is required prior to full application submission. 	<ul style="list-style-type: none"> • The maximum period of performance is 4 years. • The maximum allowable funding for the entire period of performance is \$1.4M for total costs.* 	<p>Pre-Application (Letter of Intent): September 15, 2026 5:00 p.m. Eastern time</p> <p>Application: October 1, 2026 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Pilot Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942526OCRPPA</p>	<p>Investigators at the level of postdoctoral fellow or clinical fellow, or equivalent.</p>	<ul style="list-style-type: none"> • Supports innovative, high-risk/high-reward research in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward. <ul style="list-style-type: none"> ○ Innovation is an important review criterion. ○ The goal is to develop preliminary data; thus, preliminary data are not required but are allowed. ○ Applications cannot support clinical trials. ○ Encourages research aimed at extending the lives of advanced-state and recurrent patients. • Reviewers will be blinded to the identity of the PI, collaborators and their organization(s). • <i>The OCRP requires submission of a Preproposal and will blind reviewers to the names of investigators and organizations during review; full application submission is by invitation only.</i> • <i>Clinical trials are not allowed.</i> 	<ul style="list-style-type: none"> • The maximum period of performance is 2 years. • The maximum allowable funding for the entire period of performance is \$350,000 for total costs. * 	<p>Pre-Application (Preproposal): July 13, 2026 5:00 p.m. Eastern time</p> <p>Application: October 1, 2026 11:59 p.m. Eastern time</p>

*Total costs include direct and indirect costs.